GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Total Current Assets

Infant Bacterial Therapeutics AB (OSTO:IBT B) Total Current Assets : kr230.61 Mil (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Infant Bacterial Therapeutics AB's total current assets for the quarter that ended in Dec. 2024 was kr230.61 Mil.

Infant Bacterial Therapeutics AB Total Current Assets Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Total Current Assets Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 438.12 397.09 339.03 341.56 230.61

Infant Bacterial Therapeutics AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 341.56 339.31 287.08 230.14 230.61

Infant Bacterial Therapeutics AB Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Infant Bacterial Therapeutics AB's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=223.388+1.292+0+5.93
=230.61

Infant Bacterial Therapeutics AB's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=223.388+1.292+0+5.93
=230.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Infant Bacterial Therapeutics AB  (OSTO:IBT B) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Infant Bacterial Therapeutics AB's Liquidation Value for the quarter that ended in Dec. 2024 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=223.388-69.303+0.75 * 0+0.5 * 0
=154.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB Total Current Assets Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Total Current Assets
Comparable Companies
OSTO:FLUO OSTO:IRLAB A OSTO:MAGLE OSTO:INIT OSTO:CANTA OSTO:IVACC OSTO:XBRANE OSTO:LIPUM OSTO:ISOFOL OSTO:SANION VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
9IB:Germany
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Website
https://www.ibtherapeutics.com
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines